PI3K inhibitors have extensively studied mechanisms of action and have been actively investigated as anticancer treatments. Some PI3K inhibitors (e.g. Idelalisib, Copanlisib, Duvelisib, and Alpelisib) have been approved for various lymphomas. More PI3K inhibitors (e.g. Taselisib, Buparlisib, Umbralisib and Voxtalisib) have entered into late-stage human clinical trials for a broader spectrum of cancers.